DTIL - CIK 0001357874
PRECISION BIOSCIENCES INC trades as DTIL. In its fiscal 2025 annual report the company posted revenue of $34.26M, down 50.1% from the prior year and net income of -$45.72M. This page tracks PRECISION BIOSCIENCES INC through 572 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years PRECISION BIOSCIENCES INC's revenue grew from $10.88M to $34.26M, a compound annual growth rate of 17.8%. Net profit margin expanded from -423.0% to -133.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-27 |
| Major company event | 8-K | 2026-05-26 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Quarterly report | 10-Q | 2026-05-05 |
The largest companies sharing PRECISION BIOSCIENCES INC's SEC industry classification (biological products, (no diagnostic substances)).
PRECISION BIOSCIENCES INC reported revenue of $34.26M for fiscal year 2025, a decrease of 50.1% year over year.
In its latest fiscal year PRECISION BIOSCIENCES INC reported a net loss of $45.72M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.